Interested in sharing the research? You can order print copies of many research publications.

Order Reprints

Newsletter Sign-Up

Keep up to date with NPC news and events by signing up for our e-newsletter E.V.I.dently, and our CER Daily Newsfeed.

Subscribe POLICY

NEWS FEEDS

Supporting Consumer Access to Specialty Medications Through Value-Based Insurance Design

Specialty pharmaceuticals are medications that consist of complex molecules, have qualities that result in costly delivery, and/or carry high costs ($600 or more per month is a common threshold). These medications are frequently used in the treatment of rheumatoid arthritis (RA), multiple sclerosis (MS), cancer and a variety of other serious health conditions.

About one quarter of total pharmaceutical spending in the commercial market is devoted to specialty medications. If current trends hold, spending on specialty medications may comprise half of all pharmaceutical spending by 2018 for commercial health care plans. These trends have invited the scrutiny of plan sponsors. To control spending, many payers and purchasers have established requirements for high cost-sharing, requirements that may trigger cost-related non-adherence for some patients.

This report, authored by A. Mark Fendrick, MD, Co-Director of the Center for Value-Based Insurance Design at the University of Michigan, Jason Buxbaum, MHSA, and NPC Director of Health Services Research Kimberly Westrich, MA, outlines that:

  • For many patients and clinical indications, high spending on specialty medications is money well spent;
  • Indiscriminate, high cost-sharing for specialty medications can be harmful to patients and employers; and
  • Payers and purchasers can deploy a variety of tactics to help assure that patients have access to the right medications.

Value-based insurance design (V-BID) is a key tactic payers and purchasers can use to promote access to high-value specialty medications. V-BID is a model of insurance design that provides more generous coverage for services that offer known, evidence-based value and less generous coverage for those where value is low. Or in other words, V-BID  shifts the focus from “how much” to “how well” we spend health care dollars. V-BID is driven by the concept of clinical nuance, which recognizes that medical services differ in the benefit they provide, as well as the benefit each individual patient experiences from a particular service.

The concept of clinical nuance and condition-specific benefit design is especially relevant for specialty medications. Specialty medications tend to deliver both great clinical benefits and have higher costs. However, the cost, as opposed to the clinical benefit and ultimate value, of specialty medications has been the sole focus of typical approaches to insurance design. Alternatively, V-BID offers a way to account for clinical nuance and, as the report notes, the fact that “many specialty medications deliver improvements in health and health-related quality of life at prices that are lower or competitive with many commonly accepted medical interventions.”

In applying V-BID to specialty medications payers and purchasers can use a variety of techniques, including:

  • Imposing no more than modest cost-sharing on high-value medications;
  • Reducing cost-sharing based on patient- or disease-specific qualifications;
  • Selectively reducing cost-sharing for patients who fail to respond as desired to another medication based on current access restrictions used by insurance companies; or
  • Using cost-sharing to encourage patient selection of high-performing providers.

To make V-BID work effectively for specialty medications, the authors point out that it will be critical to anticipate and address some of the foreseeable challenges associated with clinically nuanced benefit designs. Specifically, it will be essential that plans and plan sponsors:

  • Prepare for administrative complexity;
  • Establish incentives that engage patients early;
  • Communicate effectively about V-BID;
  • Integrate V-BID with provider-facing initiatives; and
  • Recognize that the perfect must not be the enemy of the good—or in other words, understand that comprehensive and far-reaching V-BID implementation for specialty pharmaceuticals may not be feasible immediately, but that important headway can be made by beginning with certain high-priority medications or conditions.
Newsletter Volume

E.V.I.dently: April 2016

MessageValue Assessment Through a Broader, Patient-Focused LensNPC has developed “Guiding Practices for Patient-Centered Value Assessment” to help...
Newsletter Volume

E.V.I.dently January 2016

MessageThe Importance of Evidence, Value, Access and Innovation in 2016In his annual health care outlook, NPC President Dan Leonard explains why...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Press Release

Specialty Medications: Shifting the Focus From “How Much” We Spend to “How Well” We Spend

Washington, DC, June 9, 2014—As health care decision-makers grapple with how to ensure access to specialty medications, the University of Michigan...
Press Release

Pharmaceuticals Play Key Role in Achieving ACO Quality, Cost Goals

WASHINGTON, DC, July 18, 2012–As health care providers set up accountable care organizations (ACOs) and other value-based care programs,...
Press Release

New Report Urges Employers, Researchers and Policy Makers to Rethink How They Measure Health Care Results

San Francisco, CA & Washington, DC (February 28, 2011) -- Understanding the full value of improved health, including improvements in workforce...
Press Release

NBCH eValue8™ Report Reveals Health Plans’ Ability to Align Employee Incentives to Improve Health

Washington, DC (November 30, 2009) – The current rate of health care cost increases are unsustainable and health care purchasers are increasingly...
Commentary and Testimony Page

The Importance of Evidence, Value, Access and Innovation in 2016

Last year, in our 2015 Health Care Outlook published in Chain Drug Review, I highlighted the recent announcement by the U.S. Department of Health and...
Commentary and Testimony Page

Chain Drug Review – Commentary: “Health Care Outlook for 2015”

This commentary was originally published in the January 5, 2015 issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Comments on CMS' Proposed Changes to Protected Classes

March 7, 2014Marilyn B. TavennerAdministratorCenters for Medicare & Medicaid ServicesU.S. Department of Health and Human Services200 Independence...
Commentary and Testimony Page

Synergies at Work: Realizing the Full Value of Health Investments

According to new research funded and published by the National Pharmaceutical Council, health benefits decisions based on the full value of improved...
YouTube Videos

Accountable Care Measures for High-Cost Specialty Care and Innovative Treatment

Tom Valuck, MD, MHSA, JD, partner, Discern Health, is a co-author of the white paper "Accountable Care Measures for High-Cost Specialty Care and...
YouTube Videos

Access to Specialty Medications & Value-Based Insurance Design

Specialty medications have been making health care headlines because of their effectiveness and higher costs. How can we ensure that patients will...
YouTube Videos

Shifting the Focus From "How Much" to "How Well" We Spend Our Health Care Dollars

A. Mark Fendrick, MD, director of the Center for Value-Based Insurance design at the University of Michigan, highlights the key findings from a...
YouTube Videos

Supporting Consumer Access to Specialty Medications Through Value-Based Insurance Design

Access to specialty medications is a particularly pressing issue for many people who rely on these treatments for conditions that are often very...
Blog Post

Can We Work Together to Ensure Patient Access to Treatments and Encourage Innovation?

Is it possible for all health care stakeholders to work together to develop solutions for containing costs that ensure patient access to care and...
Blog Post

The Shift to Value-Based Care: Balancing Quality Improvement with Patient Access

Over the last few years, there has been a significant shift throughout our health care system to move to a delivery and payment model known as value-...
Blog Post

#TBT: Value-Based Insurance Design & New Medicare Advantage Model

As part of our Throwback Thursday blog series, we’re taking a look at a topic that’s currently in the news and tagging it with previous research...
Blog Post

New Models Like V-BID Driving Value-Based Health Care

From accountable care organizations and bundled payments to patient-centered medical homes and value-based insurance design (V-BID), new delivery and...

Designing Successful Bundled Payment Initiatives

The National Pharmaceutical Council led a study that identified three principles intended to...

Private Sector Risk-Sharing Agreements in the US: Trends, Barriers and Prospects

A peer-reviewed study found that there are limited risk-sharing agreements (RSAs) between health...
  •  
  • 1 of 8
  • >